

MORPHOMETRIC INDICATORS OF THE PROSTATE GLAND AND THEIR DIAGNOSTIC SIGNIFICANCE

Qarshiyev Jamshidbek Elbek og'li
Student of General Medicine, Faculty of Medicine
Termiz University of Economics and Service
Bekmirzayev Eshquvvat Ro'ziboyevich
Termez University of Economics and Service,
Faculty of Medicine, Instructor
https://doi.org/10.5281/zenodo.1869925
https://doi.org/10.5281/zenodo.18796189

Abstract

This article analyzes morphometric indicators of the prostate gland and explains their diagnostic significance in benign prostatic hyperplasia, prostatitis, and prostate cancer.Imaging methods such as transrectal ultrasonography and multiparametric MRI are discussed together with digital rectal examination, laboratory testing, and histopathologic confirmation. The article also highlights measurement standardization, common sources of error, and the value of integrating quantitative morphometry with symptoms and risk stratification. Overall, accurate morphometric assessment improves diagnostic confidence, supports selection of treatment pathways, and strengthens communication among clinicians, radiologists, and pathologists.

Keywords

Prostate gland, morphometric indicators, prostate volume, prostate dimensions, transrectal ultrasound, multiparametric MRI, prostate-specific antigen, digital rectal examination, prostate biopsy, histomorphometry, benign prostatic hyperplasia, prostate cancer diagnostics

Introduction

The prostate gland is a fibromuscular and glandular organ of the male reproductive system whose morphometric characteristics have direct clinical importance in urology, radiology, pathology, and oncology. In clinical practice, the prostate is not assessed only as an anatomical structure but as a functional organ whose size, volume, zonal proportions, contour, and tissue architecture change in response to age, endocrine influences, inflammation, benign hyperplasia, and malignant transformation. For this reason, morphometric evaluation is not a secondary technical detail. It is a central component of modern diagnosis, risk stratification, treatment planning, and follow up. Accurate morphometric assessment helps distinguish physiological variation from pathology and improves interpretation of symptoms, laboratory findings, and imaging abnormalities.

From the anatomical point of view, the prostate lies below the urinary bladder, surrounds the proximal urethra, and is positioned anterior to the rectum. This topography explains the continuing utility of digital rectal examination and also the strengths of transrectal imaging. Traditional anatomy often described prostatic lobes, but contemporary radiology and pathology rely more heavily on zonal anatomy. The peripheral zone, transition zone, and central gland compartments differ in embryologic origin, tissue composition, and disease prevalence. Most clinically significant cancers arise in the peripheral zone, while benign prostatic hyperplasia most commonly develops in the transition zone. Therefore, the same total

IBMSCR | Volume 6, Issue 02, February

gland volume may have very different diagnostic implications depending on how that volume is distributed across zones. Morphometric analysis becomes most useful when total measurements are linked to zonal anatomy rather than interpreted in isolation.

The core morphometric parameters used in routine assessment are craniocaudal length, transverse width, and anteroposterior height. These are measured by transrectal ultrasonography, transabdominal ultrasonography in selected settings, or magnetic resonance imaging. In everyday reporting, these orthogonal dimensions are combined using the ellipsoid formula to estimate prostate volume. Although simple, this calculation remains highly influential because prostate volume affects diagnostic interpretation in several ways. It contributes to the evaluation of lower urinary tract symptoms, supports procedural planning for biopsy or surgery, influences medical therapy selection in benign prostatic enlargement, and enables calculation of prostate specific antigen density. In other words, volume is not only a descriptive variable but a decision making variable.

Morphometric assessment of the prostate must also account for age related remodeling. During adolescence and early adulthood, growth is hormonally regulated and reaches a relatively stable mature phase. Later in life, and particularly after middle age, the gland often enlarges due to nodular hyperplasia, usually centered in the transition zone. This process can produce a progressive increase in total prostate volume, but symptom severity does not always rise in parallel with gland size. Some patients with moderate enlargement have significant obstruction, whereas others with larger glands report relatively mild symptoms. This apparent mismatch highlights an important principle in morphometric diagnosis: volume alone is insufficient. The pattern of enlargement, degree of intravesical protrusion, urethral compression, bladder wall changes, postvoid residual urine, and associated functional findings must be integrated to explain the clinical picture.

Among derived morphometric indicators, prostate specific antigen density has a particularly strong diagnostic role. PSA density is obtained by dividing the serum PSA value by the measured prostate volume. This index improves interpretation of PSA because PSA production is influenced not only by malignancy but also by benign enlargement and inflammation. A mildly elevated PSA in a markedly enlarged prostate may reflect increased benign tissue mass, whereas a similar PSA in a small prostate may raise concern for clinically significant malignancy. As a result, PSA density can refine triage decisions, support risk discussions, and complement imaging based pathways. The usefulness of PSA density depends on measurement quality. If volume is overestimated or underestimated because of poor imaging technique, the derived density loses reliability. This is one reason standardized morphometric measurement is essential.



Materials and methods

This work is a narrative academic review prepared in an IMRAD style on the topic of prostate gland morphometric indicators and diagnostic methods. The manuscript synthesizes standard concepts used in urologic examination, ultrasonography, magnetic resonance imaging, and histopathologic assessment. The methodological focus is educational and analytic rather than experimental, with emphasis on clinically used morphometric variables and their interpretation in routine diagnostic workflows.

The principal variables considered include prostate length, transverse width, anteroposterior height, estimated total volume using the ellipsoid approach, zonal enlargement patterns, contour and capsular features, lesion dimensions on imaging, and derived indices such as PSA density. Diagnostic modalities discussed include history taking, digital rectal examination, serum PSA testing, ultrasonography, multiparametric MRI, and biopsy with pathomorphometric confirmation when indicated.

For interpretive consistency, the article prioritizes standardized measurement technique, reproducibility, and integration of quantitative data with clinical context. Morphometric findings are discussed across three major clinical domains: benign prostatic hyperplasia, inflammatory disease, and suspected or confirmed prostate carcinoma.

Results and discussion

Diagnostic evaluation usually begins with history and physical examination. Symptoms such as weak stream, hesitancy, intermittency, urgency, nocturia, dysuria, pelvic discomfort, hematuria, or urinary retention can point toward different disease processes. Family history of prostate cancer, previous prostatitis, metabolic disease, medication use, and age all influence pretest probability. Digital rectal examination can detect asymmetry, nodularity, firmness, diffuse enlargement, or tenderness, but it is limited in sensitivity and reproducibility. Morphometric imaging fills this gap by quantifying what physical examination can only estimate. Ultrasonography can rapidly characterize gland size, residual urine, and gross

IBMSCR | Volume 6, Issue 02, February

architecture, while MRI can provide more detailed zonal analysis, lesion characterization, and local staging information when cancer is suspected.

In benign prostatic hyperplasia, morphometry is central to both diagnosis and management. Hyperplasia typically produces transition zone enlargement with nodular heterogeneity and varying stromal and glandular components. The resulting changes may include an increase in total gland volume, disproportionate growth of the transition zone, compression of the peripheral zone, urethral narrowing, and protrusion into the bladder lumen. Intravesical prostatic protrusion, in particular, has practical clinical relevance because it may correlate with outlet obstruction and treatment response in selected patients. Morphometric assessment also supports therapeutic planning. Volume thresholds are often considered when choosing between watchful waiting, pharmacologic therapy, minimally invasive procedures, and surgical approaches. Thus, measurements directly influence management pathways rather than serving as purely descriptive observations.

Morphometric findings in prostatitis are generally less specific than in hyperplasia or carcinoma, but they still contribute useful information when interpreted carefully. Acute prostatitis may produce diffuse gland enlargement, altered echogenicity, increased vascularity on Doppler examination, and marked tenderness during clinical assessment. Chronic inflammatory conditions can show calcifications, patchy architectural changes, focal asymmetry, or nonspecific volume variation. None of these features alone can establish the diagnosis, because overlap with benign age related changes is common. However, morphometric evaluation helps exclude abscess formation, identify retention related consequences, and document baseline anatomy before follow up. In recurrent or persistent symptoms, serial comparison of size and internal architecture can also help determine whether the dominant process is inflammatory, obstructive, or suspicious for neoplasia.

In the setting of suspected prostate cancer, morphometric analysis has expanded from total gland measurement to lesion focused quantification. Multiparametric MRI integrates T2 weighted imaging, diffusion weighted imaging, and often dynamic contrast enhanced sequences to characterize lesions and assign standardized suspicion categories. Lesion size, shape, border characteristics, and relationship to the capsule are all morphometric factors that affect reporting and management. A small, well circumscribed lesion may be monitored differently from a larger or more irregular lesion with extracapsular contact. Total prostate volume remains important in this context because it influences PSA density and affects lesion conspicuity during biopsy planning. In larger glands, sampling error may increase if biopsy strategies are not adjusted appropriately, which again demonstrates the practical importance of morphometric data.

Pathomorphometric evaluation provides the definitive diagnostic reference when tissue is obtained by biopsy or surgery. Histopathology assesses glandular architecture, nuclear atypia, stromal response, perineural invasion, and infiltrative growth patterns. It also generates quantitative and semi quantitative metrics such as tumor length in cores, percentage of involvement, number of positive cores, and grade group. Modern diagnostic communication increasingly links imaging morphometry with pathologic morphometry. Radiologists describe lesion location, size, and zonal assignment, while pathologists report corresponding tumor burden and grade. This correlation improves diagnostic confidence, reduces sampling ambiguity, and strengthens treatment planning. In active surveillance protocols, repeated

IBMSCR | Volume 6, Issue 02, February

morphometric and pathomorphometric assessments are often combined to monitor disease stability or progression over time.

A structured diagnostic algorithm for prostate disease should therefore integrate clinical, laboratory, and morphometric information in a stepwise manner. In patients presenting with lower urinary tract symptoms, the initial goal is to determine whether symptoms are primarily due to benign enlargement, infection, neurogenic dysfunction, or another cause. Morphometric ultrasound may establish gland volume, estimate residual urine, and detect gross structural abnormalities. In patients with elevated PSA or abnormal rectal examination, the objective shifts toward cancer risk stratification. Here, total prostate volume and PSA density provide context, and multiparametric MRI may identify lesions requiring targeted biopsy. When tissue diagnosis is obtained, pathomorphometric findings confirm disease type and biological aggressiveness. The overall quality of this pathway depends heavily on the quality and reproducibility of the initial measurements.

Standardization is one of the most important principles in prostate morphometry. Measurements should be performed in clearly defined planes, using appropriate probe positioning and image optimization. The examiner should document the method used, especially if serial comparisons are expected. Inconsistent technique can produce apparent changes in volume that reflect measurement error rather than biological change. This is particularly relevant in follow up of benign enlargement, assessment of response to therapy, and active surveillance of low risk malignancy. Reproducible morphometric practice also improves interdisciplinary communication because clinicians can compare values across time and across institutions with greater confidence.



Despite major progress in imaging and quantitative assessment, important limitations remain. The ellipsoid formula may underestimate or overestimate actual volume in irregular or markedly lobulated glands. Ultrasound measurements are operator dependent and can be affected by patient discomfort, probe angle, or incomplete visualization. MRI provides superior soft tissue contrast but is more expensive, less available in some settings, and susceptible to

IBMSCR | Volume 6, Issue 02, February

interpretation variability. PSA density improves risk assessment but cannot fully separate benign inflammation from malignancy in all patients. Pathology is definitive for diagnosis but depends on representative sampling, and biopsy may miss significant lesions if targeting is suboptimal. These limitations do not reduce the value of morphometry; rather, they emphasize that morphometric indicators must be interpreted within a broader clinical framework.

The educational and scientific importance of prostate morphometry is also increasing. With the growth of machine learning and quantitative radiology, automated segmentation and volumetric analysis are being incorporated into research and, increasingly, clinical workflows. These methods may improve reproducibility, reduce observer variation, and enable more detailed analysis of zonal volumes and lesion geometry. At the same time, human expertise remains essential. Automated tools are only as reliable as the image quality and validation standards supporting them. For students and clinicians, mastering basic morphometric principles remains indispensable because correct interpretation requires understanding anatomy, pathology, and the clinical context in which measurements are obtained.

In conclusion, morphometric indicators of the prostate gland form a quantitative foundation for diagnosis across benign and malignant urologic disease. Total volume, orthogonal dimensions, zonal proportions, contour changes, intravesical protrusion, lesion size, and derived indices such as PSA density each provide clinically meaningful information. When measured with standardized technique and interpreted together with symptoms, laboratory results, physical examination, and pathology, these indicators significantly improve diagnostic precision and patient management. Therefore, the study of prostate morphometry is not merely descriptive anatomy. It is a practical diagnostic discipline that links imaging, laboratory medicine, pathology, and clinical decision making in contemporary urology.

Conclusion

Prostate morphometry is not limited to measuring size; it is a clinically meaningful framework for interpreting urinary symptoms, PSA abnormalities, imaging findings, and biopsy planning. Accurate measurement of orthogonal dimensions, total volume, zonal changes, lesion size, and derived parameters such as PSA density enhances diagnostic precision in both benign and malignant disease. When standardized methods are used and findings are interpreted together with clinical and laboratory data, morphometric indicators substantially improve diagnostic confidence and management quality in contemporary urologic practice.

References:

1.Rizaev J.A., Rakhimov N.M., Kadirov Kh.Kh., Shakhanova Sh.Sh. Disparity in the prevalence of prostate cancer in urban and rural settings (on the example of Samarkand region). Doctor's Bulletin, 2022, No. 3(106), pp. 102–106.
2.Takhirovich T.I. Modern diagnostics of prostate cancer. Modern Education / Collection of Scientific Articles in Medicine (electronic scientific source), 2025.
3.Kadirov Kh.Kh., Rakhimov N.M. The importance of PSA and clinical indicators in the diagnosis of prostate cancer. Proceedings of Samarkand State Medical University, 2021, pp. 45–52.
4.Rizaev J.A., Shakhanova Sh.Sh. Organizational and clinical aspects of early detection of prostate diseases in men. A New Day in Medicine, 2021, No. 4, pp. 118–124.
5.Kadirov Kh.Kh. Modern diagnostic methods in urology and andrology. Tashkent: Medical Publishing House, 2020. 216 p.

6.Rakhimov N.M. Correlation between ultrasound diagnostics and morphological examinations in prostate diseases. Journal of Uzbekistan Medicine, 2020, No. 6, pp. 67–73.
7.Shakhanova Sh.Sh., Rizaev J.A. Risk factors and screening approaches for prostate cancer. Problems of Biology and Medicine, 2023, No. 2, pp. 89–95.
8.Kadirov Kh.Kh., Rakhimov N.M., Rizaev J.A. Clinical, laboratory, and instrumental diagnostic algorithms in prostate pathologies. Samarkand: SamSMU Scientific-Methodological Publication, 2022. 134 p.orthogonal measurements and the ellipsoid formula.